about
Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerizationParkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survivalp25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathiesp25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophyDown-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stressAlpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severityAlpha-synuclein and presynaptic function: implications for Parkinson's disease.Identification of synaptosomal proteins binding to monomeric and oligomeric α-synuclein.Pathogenic effects of alpha-synuclein aggregation.Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease.Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo.Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathologyTubulin polymerization-promoting protein (TPPP/p25α) promotes unconventional secretion of α-synuclein through exophagy by impairing autophagosome-lysosome fusionStructural and functional characterization of two alpha-synuclein strains.The glycan structure of albumin Redhill, a glycosylated variant of human serum albumin.Protein Partners of α-Synuclein in Health and Disease.DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro.Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells.Caspase-mediated parkin cleavage in apoptotic cell death.Caspase I-related protease inhibition retards the execution of okadaic acid- and camptothecin-induced apoptosis and PAI-2 cleavage, but not commitment to cell death in HL-60 cells.Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis.Localization of transglutaminase-reactive glutamine residues in bovine osteopontin.p25alpha is flexible but natively folded and binds tubulin with oligomeric stoichiometry.Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.Receptors for alpha 2-macroglobulin- and pregnancy zone protein-proteinase complexes in the human placental syncytiotrophoblast.Cell association and degradation of pregnancy zone protein-chymotrypsin complex in cultured human monocytes.Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.Proteasomal inhibition by alpha-synuclein filaments and oligomers.Characterizing the dynamics of α-synuclein oligomers using hydrogen/deuterium exchange monitored by mass spectrometry.Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.Incipient intranuclear inclusion body disease in a 78-year-old woman.alpha-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy.Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.Oligodendrocytes within astrocytes ("emperipolesis") in the cerebral white matter in hepatic and hypoglycemic encephalopathy.A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats.
P50
Q24291150-A08AB384-A5A4-4750-A5CB-058E95CF255CQ24300743-3A50AE3A-5A22-4236-AB8C-5247894E928DQ24320549-4D98CC8F-7D15-4A27-B290-5366A05E61E3Q24682056-E0E11B95-3EE6-413D-82EF-E24ED2C0F26FQ28575936-677BCC8C-1C37-481A-8DF2-EE6393FAD2E6Q28579526-8D1E59F9-7A7D-43CE-9658-945B6593B19FQ30856480-5E3F207D-62D3-4604-AFED-F8EE6E3F502DQ34460662-321D2837-6515-439B-8B89-7D967447B41AQ34995107-35F283C0-8985-4DA9-A340-0BB1787482BCQ35557260-094CE220-CE1F-4AF8-A022-80C85646B20DQ36080000-5C6E5F35-73A3-431A-BA2F-3765A728EAF8Q36100354-AE98D0BE-7A14-44EE-8323-205E394C5657Q36543608-62B86876-2998-4B4D-98D1-1112A30A21A1Q36660813-014B21C0-51DD-440F-85A7-86AEC5A6D168Q36928990-1490ADD7-A8CB-4701-AD6C-AB56F913A063Q37305236-35A9DE29-6510-4B22-AFDD-9710637EF512Q38294116-B9EED83D-240D-4953-BE62-BD7B18CFF735Q38759798-94DF2F62-3E4F-4BF3-8FDA-C3D3521E36DEQ38972171-E5016908-43EA-4F74-B45D-4FB078423355Q38987375-5B67CB6D-0AD0-4DED-8EBE-E146DB219187Q39885727-858FD222-CA1C-4665-8662-C2E8A25C7F9CQ40751610-01BA2FE1-34BD-4866-A882-BBD2AA7A9AD6Q40960316-F9A1A157-AD8C-4B5D-90D6-ED750A303CFDQ41431314-2CAA8EE0-B403-4BE7-9390-DC61F497EB4AQ41770359-158899B1-EF69-47CA-BC31-65C7DBA3DB02Q41910014-74A8E137-36F6-43B9-A61A-98F3E669D5FDQ42939567-2B7CEE78-1015-4427-A845-F3B14F1DB226Q43247253-F5E046E7-7097-44BA-BD73-EFECC0001111Q43448353-415D1173-A455-4A5C-8943-31A9460CC151Q43839844-ACCC95D0-68C1-43DA-A53A-E41F25F700A0Q44143951-1E216FC9-9F24-41F2-BBDB-78285983E011Q44719233-BC048F97-239E-45A9-8A62-477B15C093D4Q46579839-4D22F5EF-DAE2-422E-8954-EE4498157323Q48091249-5088D759-BCB6-4263-93E7-965687D3090BQ48108864-15947073-5022-4B5A-BC18-D0805C9A53E3Q48327676-6936191A-8284-4705-81B4-6EB4DAB73E96Q48384247-7FD3F356-14FD-4B0F-BF1A-F95E39C60B3CQ48625399-AB06669C-2EC9-40CB-BB1F-E97CB52AFF69Q49613405-77D3164C-25EF-4F0B-BBFC-ABE45728E473Q50145319-A5684F77-2572-4462-BB76-610EA97ED354
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-4439-9020
@en
name
Poul Henning Jensen
@ast
Poul Henning Jensen
@en
Poul Henning Jensen
@es
Poul Henning Jensen
@nl
type
label
Poul Henning Jensen
@ast
Poul Henning Jensen
@en
Poul Henning Jensen
@es
Poul Henning Jensen
@nl
prefLabel
Poul Henning Jensen
@ast
Poul Henning Jensen
@en
Poul Henning Jensen
@es
Poul Henning Jensen
@nl
P106
P1153
7402088777
P31
P496
0000-0002-4439-9020